Abstract | BACKGROUND: METHODS: A consecutive series of 68 CMV high-risk lung transplant recipients (D+/R-, D+/R+), who had a minimum follow-up of 1 year posttransplant were analyzed. Thirty patients (44.1%) received single GAN prophylaxis for 3 months (control group) and 38 recipients (55.9%) received GAN together with CMV-IG 7 times during the first postoperative month (study group). Median follow-up was 16.5 months in the control and 23.8 months in the study group (P = 0.54). RESULTS: Five CMV-related deaths (16.7%) occurred in the control group (P = 0.014). Fifteen recipients suffered from CMV pneumonitis and three patients had CMV syndrome. In the control group, 13 recipients (43.3%) suffered from clinically manifested CMV disease compared to 5 (13.2%) in the study group (P = 0.007). Additionally, recipient survival was significantly better in the study group (P = 0.01). One year freedom from CMV affection was 52.1% in the control and 71.5% in the study group (P = 0.027). Three-year freedom from BOS was significantly higher in the study group (54.3% vs. 82%, P = 0.024). CONCLUSIONS: In CMV high risk patients, additional CMV-IG administration seems to be effective to reduce CMV-related morbidity and to avoid CMV-related mortality. Reduced incidence of BOS may result from improved CMV prevention, although randomized trials are warranted.
|
Authors | Elfriede Ruttmann, Christian Geltner, Brigitte Bucher, Hanno Ulmer, Daniel Höfer, Herbert B Hangler, Severin Semsroth, Raimund Margreiter, Günther Laufer, Ludwig C Müller |
Journal | Transplantation
(Transplantation)
Vol. 81
Issue 10
Pg. 1415-20
(May 27 2006)
ISSN: 0041-1337 [Print] United States |
PMID | 16732179
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antiviral Agents
- Immunoglobulins
- Immunoglobulins, Intravenous
- cytomegalovirus-specific hyperimmune globulin
- Ganciclovir
|
Topics |
- Adult
- Antiviral Agents
(therapeutic use)
- Bronchiolitis Obliterans
(prevention & control)
- Cytomegalovirus Infections
(immunology, prevention & control)
- Drug Therapy, Combination
- Female
- Ganciclovir
(therapeutic use)
- Humans
- Immunization, Passive
- Immunoglobulins
(therapeutic use)
- Immunoglobulins, Intravenous
- Lung Transplantation
(adverse effects)
- Male
- Middle Aged
- Retrospective Studies
|